At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 1.84: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.03BCNY753.70M · vs all stocks (USD)
Revenue (TTM)
2.36BCNY353.46M · vs all stocks (USD)
Profit Margin
-5.48%Beta
0.2610xvs all stocks
52-Week Change
-37.31%vs all stocks
Market Capitalization
5.03BCNY753.70M · vs all stocks (USD)
Enterprise Value
6.18BCNY926.47M · vs all stocks (USD)
Price to Sales (TTM)
2.15xPrice to Book (MRQ)
1.57xEnterprise to Revenue
2.62xEnterprise to EBITDA
43.22xGross Margin
33.68%Profit Margin
-5.48%Operating Margin
0.98%Return on Assets (TTM)
0.24%Return on Equity (TTM)
-4.06%Revenue (TTM)
2.36BCNY353.46M · vs all stocks (USD)
Revenue per Share (TTM)
1.64CNYUpdated Nov 19, 2026Quarterly Revenue Growth
-31.00%Gross Profit (TTM)
851.87MCNY127.66M · vs all stocks (USD)
EBITDA (TTM)
227.61MCNY34.11M · vs all stocks (USD)
Net Income (TTM)
-129.24MCNY-19.37M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-61.60%Operating Cash Flow (TTM)
229.01MCNY34.32M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
21.24MCNY3.18M · vs all stocks (USD)
5-Year Average Dividend Yield
0.87%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
19.28MCNYFY2025 · Dec 31, 2025Revenue
3.05BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.60BCNYFY2025 · Dec 31, 2025Gross Profit
1.44BCNYFY2025 · Dec 31, 2025Operating Income
227.20MCNY34.05M · vs all stocks (USD)
Pre-tax Income
40.47MCNYFY2025 · Dec 31, 2025Income Tax Expense
143.60MCNYFY2025 · Dec 31, 2025Net Income
-103.12MCNYFY2025 · Dec 31, 2025EBIT
44.16MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
227.61MCNYFY2025 · Dec 31, 2025Research & Development
17.96MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
716.64MCNYFY2025 · Dec 31, 2025Other Operating Expenses
43.94MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
634.49KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
3.69MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.0800CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.0800CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.30BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.30BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-103.12MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-1.24MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
786.56MCNYFY2025 · Dec 31, 2025Free Cash Flow
685.20MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
340.89MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-103.12MCNYFY2025 · Dec 31, 2025Other Non-cash Items
69.38MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
382.70MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
437.61MCNYFY2025 · Dec 31, 2025Capital Expenditures
-101.36MCNYFY2025 · Dec 31, 2025Net Acquisitions
0.00CNYFY2025 · Dec 31, 2025Purchase of Investments
-10.00MCNYFY2025 · Dec 31, 2025Sale of Investments
16.47MCNYFY2025 · Dec 31, 2025Other Investing Activity
108.70KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-94.78MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.17BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.72BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-62.48MCNYFY2025 · Dec 31, 2025Other Financing Charges
-17.33MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-636.44MCNYFY2025 · Dec 31, 2025Shares Outstanding
1.40BSharesUpdated Nov 19, 2026Float Shares
1.12BSharesUpdated Nov 19, 2026% Held by Insiders
33.18%vs all stocks
% Held by Institutions
0.60%vs all stocks
Total Cash (MRQ)
188.33MCNY28.22M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.1380CNYUpdated Nov 19, 2026Total Debt (MRQ)
1.06BCNY158.87M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3311xCurrent Ratio (MRQ)
0.9940xBook Value per Share (MRQ)
2.33CNYUpdated Nov 19, 2026Total Assets
6.20BCNY928.76M · vs all stocks (USD)
Total Current Assets
2.72BCNYFY2025 · Dec 31, 2025Total Liabilities
3.02BCNYFY2025 · Dec 31, 2025Total Non-current Assets
3.47BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
223.14MCNYFY2025 · Dec 31, 2025Total Current Liabilities
2.80BCNYFY2025 · Dec 31, 2025Cash
348.71MCNYFY2025 · Dec 31, 2025Cash Equivalents
6.09MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
354.80MCNYFY2025 · Dec 31, 2025Accounts Receivable
1.29BCNYFY2025 · Dec 31, 2025Inventory
665.85MCNYFY2025 · Dec 31, 2025Accounts Payable
764.77MCNYFY2025 · Dec 31, 2025Short-term Debt
1.08BCNYFY2025 · Dec 31, 2025Other Current Liabilities
51.93MCNYFY2025 · Dec 31, 2025Long-term Debt
152.59MCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.40BCNYFY2025 · Dec 31, 2025Retained Earnings
1.49BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.17BCNY475.78M · vs all stocks (USD)
Treasury Stock
219.59MCNYFY2025 · Dec 31, 202552-Week Low
3.58CNYUpdated Nov 19, 202652-Week High
5.84CNYUpdated Nov 19, 202652-Week Change
-37.31%vs all stocks
Beta
0.2610xvs all stocks
50-Day MA
4.50CNYUpdated Nov 19, 2026200-Day MA
4.67CNYUpdated Nov 19, 2026Avg 10-Day Volume
7.74MSharesUpdated Nov 19, 2026Avg 30-Day Volume
6.11MSharesUpdated Nov 19, 2026Diluted EPS (TTM)
-0.0900CNYUpdated Nov 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 1.84: grey zoneSignificant
Altman Z-Score: 1.84
High earnings qualityNotable
Earnings Quality Score: 0.93
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanxi Zhendong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Collegium Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cybin Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Arrivent Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Chongqing Pharscin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hpgc Renmintongtai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pacific Biosciences of California, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cytek Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
0009K0
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sana Biotechnology, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk